Veradermics, Incorporated (NYSE:MANE) — Market Cap & Net Worth
Market Cap & Net Worth: Veradermics, Incorporated (MANE)
Veradermics, Incorporated (NYSE:MANE) has a market capitalization of $3.80 Billion ($3.80 Billion) as of June 17, 2026. Listed on the NYSE stock exchange, this USA-based company holds position #4344 globally and #1464 in its home market, demonstrating a 0.70% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Veradermics, Incorporated's stock price $90.95 by its total outstanding shares 41778687 (41.78 Million). Review Veradermics, Incorporated (MANE) financial obligations to assess the company's total debt and financial obligations.
Veradermics, Incorporated Market Cap History: 2026 to 2026
Veradermics, Incorporated's market capitalization history from 2026 to 2026. Data shows growth from $3.80 Billion to $3.80 Billion (0.00% CAGR).
Veradermics, Incorporated Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Veradermics, Incorporated's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of MANE by Market Capitalization
Companies near Veradermics, Incorporated in the global market cap rankings as of June 17, 2026.
Key companies related to Veradermics, Incorporated by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #442 globally with a market cap of $63.33 Billion USD.
- UCB SA (BR:UCB): Ranked #550 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #574 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $453.17 |
| #442 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $63.33 Billion | $614.73 |
| #550 | UCB SA | BR:UCB | $49.68 Billion | €250.00 |
| #574 | Argen-X | BR:ARGX | $47.14 Billion | €755.80 |
Veradermics, Incorporated Historical Marketcap From 2026 to 2026
Between 2026 and today, Veradermics, Incorporated's market cap moved from $3.80 Billion to $ 3.80 Billion, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $3.80 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of Veradermics, Incorporated was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.80 Billion USD |
| MoneyControl | $3.80 Billion USD |
| MarketWatch | $3.80 Billion USD |
| marketcap.company | $3.80 Billion USD |
| Reuters | $3.80 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Veradermics, Incorporated
Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy. Additionally, it engages in t… Read more